miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis
Oncotarget2010Vol. 1(8), pp. 710–720
Citations Over TimeTop 10% of 2010 papers
Michiel Smits, Jonas A. Nilsson, Shahryar E. Mir, Petra M. van der Stoop, Esther Hulleman, Johanna M. Niers, Philip C. De Witt Hamer, Víctor E. Márquez, Jacqueline Cloos, Anna M. Krichevsky, David P. Noske, Bakhos A. Tannous, Thomas Würdinger
Abstract
Our results indicate that EZH2 has a versatile function in GBM progression and that its overexpression is at least partly due to decreased miR-101 expression. Inhibition of EZH2 may be a potential therapeutic strategy to target GBM proliferation, migration, and angiogenesis.
Related Papers
- → Circ_0030998 promotes tumor proliferation and angiogenesis by sponging miR-567 to regulate VEGFA in colorectal cancer(2021)25 cited
- → G9a: An Emerging Epigenetic Target for Melanoma Therapy(2021)14 cited
- → The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma(2017)20 cited
- → Abstract B30: Regulation of angiogenesis by the VEGF/miR-101/EZH2 axis(2010)
- → Abstract 2011: Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A against non-small cell lung cancer cells(2011)